A5009622798- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Kruppel-like factors research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Blood transfusion and management
- Blood donation and transfusion practices
- Blood groups and transfusion
- Venous Thromboembolism Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Hemoglobinopathies and Related Disorders
- Autopsy Techniques and Outcomes
- Immunodeficiency and Autoimmune Disorders
- Macrophage Migration Inhibitory Factor
- Cytokine Signaling Pathways and Interactions
- Lymphoma Diagnosis and Treatment
- Artificial Intelligence in Healthcare and Education
- COVID-19 Clinical Research Studies
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Hematopoietic Stem Cell Transplantation
- Research on Leishmaniasis Studies
- Mast cells and histamine
- Muscle Physiology and Disorders
- Cancer Mechanisms and Therapy
- Multiple Myeloma Research and Treatments
University College London
2021-2024
University College London Hospitals NHS Foundation Trust
2021-2024
University College Hospital
2023-2024
Guy's and St Thomas' NHS Foundation Trust
2015-2021
King's College London
2017-2021
Guy's Hospital
2015-2020
National Health Service
2019
London Borough of Southwark
2018
St Thomas' Hospital
2015
Summary The reported higher risk of maternal and fetal complications in women with myeloproliferative neoplasms ( MPN ) poses challenge during pregnancy. A national prospective study outcomes pregnant a diagnosis was undertaken via the United Kingdom Obstetric Surveillance System between January 2010 December 2012. Fifty‐eight were identified; 47 (81%) essential thrombocythaemia, five (9%) polycythaemia vera, myelofibrosis one (2%) ‐unclassified. There 58 live births. incidence miscarriage...
Summary The seasonal influenza A vaccine is recommended for patients with myeloproliferative neoplasms (MPNs). We hypothesised that immune deregulation associated MPNs may affect the response gained following vaccinations when compared to healthy controls. Using deep immunophenotyping high‐dimensional single‐cell analysis and mass cytometry we could demonstrate an altered in MPN vaccination. found prior vaccination, had reduced numbers of naive CD4 T cells. Furthermore, at 3‐weeks 3‐months...
TPS6592 Background: PV is a myeloproliferative neoplasm characterized by overproduction of red blood cells and increased risk thrombosis. Patients may require frequent therapeutic phlebotomies (TP) alone or in combination with cytoreductive therapy to maintain hematocrit (HCT) <45%. Hepcidin regulates iron homeostasis but downregulated PV, increasing availability for erythropoiesis, which complicates TP optimization. In phase 2 study (REVIVE, NCT04057040), rusfertide led rapid, sustained,...
Abstract Approximately 10% to 15% of patients with essential thrombocythemia (ET) lack the common driver mutations, so-called “triple-negative” (TN) disease. We undertook a systematic approach investigate for somatic mutations and delineate gene expression signatures in 46 TN compared results those known healthy volunteers. Deep, error-corrected, next-generation sequencing peripheral blood mononuclear cells using HaloPlexHS platform whole-exome was performed. Using this platform, 10 (22%)...
Myelofibrosis (MF) is a rare haematopoietic disorder, commonly diagnosed in the 6th decade: less than 20% are before age of 50 years. In this retrospective study we included all patients given diagnosis World Health Organization-defined primary or secondary MF when aged ≤50 Forty-three with median 43 years were included. Median follow up was 44 months. Twenty-two (51%) harboured JAK2 V617F mutation, 18/43 (42%) CALR, 0/43 (0%) MPL mutations and 3/43 (7%) 'Triple Negative' (TN). At time...
Summary Standard first‐line therapy choice for essential thrombocythaemia ( ET ) requiring cytoreduction, supported by randomized trials, is low‐dose aspirin with hydroxycarbamide, but the role of recombinant interferon‐alfa IFN α)‐2a/2b and pegylated PEG )‐ ‐α‐2a/2b increasingly highlighted. Longer‐term outcome data, however, remains somewhat scarce, particularly in ‘real world'. We hereby report on a large, well‐annotated cohort patients from single referral centre undergoing either α or...
Efforts to reduce platelet wastage in hospital blood banks have focused on ordering policies, but the predominant practice of issuing oldest unit first may not be optimal when some units are returned unused. We propose a novel, machine learning (ML)-guided policy increase likelihood being reissued before expiration. Our ML model trained predict returns 17,297 requests for platelets gave AUROC 0.74 9,353 held-out requests. Prior development we built simulation bank operation that incorporated...